Next Article in Journal
N,N′-Diaryldihydrophenazines as a Sustainable and Cost-Effective Alternative to Precious Metal Complexes in the Photoredox-Catalyzed Alkylation of Aryl Alkyl Ketones
Previous Article in Journal
Efficient Antibacterial/Antifungal Activities: Synthesis, Molecular Docking, Molecular Dynamics, Pharmacokinetic, and Binding Free Energy of Galactopyranoside Derivatives
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Decrypting the Potential of Nanotechnology-Based Approaches as Cutting-Edge for Management of Hyperpigmentation Disorder

1
Department of Pharmaceutics, MM College of Pharmacy, Maharishi Markandeshwar (Deemed to Be University), Mullana, Ambala 133207, Haryana, India
2
Chitkara College of Pharmacy, Chitkara University, Rajpura 140401, Punjab, India
3
School of Health Sciences &Technology, University of Petroleum and Energy Studies, Bidholi, Dehradun 248007, Uttarakhand, India
4
Janta College of Pharmacy, Butana, Sonipat 131302, Haryana, India
5
Department of Pharmacology, MM College of Pharmacy, Maharishi Markandeshwar (Deemed to Be University), Mullana, Ambala 133207, Haryana, India
6
Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Alkharj 16278, Saudi Arabia
7
Substance Abuse and Toxicology Research Centre, Jazan University, Jazan 45142, Saudi Arabia
8
Center for Transdisciplinary Research, Department of Pharmacology, Saveetha Dental College, Saveetha Institute of Medical and Technical Science, Saveetha University, Chennai 602117, Tamil Nadu, India
9
Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 410028 Oradea, Romania
10
Doctoral School of Biomedical Sciences, University of Oradea, 410087 Oradea, Romania
*
Authors to whom correspondence should be addressed.
Molecules 2023, 28(1), 220; https://doi.org/10.3390/molecules28010220
Submission received: 3 November 2022 / Revised: 15 December 2022 / Accepted: 19 December 2022 / Published: 26 December 2022

Abstract

:
The abundant synthesis and accretion of melanin inside skin can be caused by activation of melanogenic enzymes or increase in number of melanocytes. Melasma is defined as hyperpigmented bright or dark brown spots which are symmetrically distributed and have serrated and irregular borders. The three general categories of pigmentation pattern include centro facial pattern, malar pattern, and mandibular pattern. Exposure to UV rays, heat, use of cosmetics and photosensitizing drugs, female sex hormonal therapies, aberrant production of melanocyte stimulating hormone, and increasing aesthetic demands are factors which cause the development of melasma disease. This review gives a brief overview regarding the Fitzpatrick skin phototype classification system, life cycle of melanin, mechanism of action of anti-hyperpigmenting drugs, and existing pharmacotherapy strategies for the treatment of melasma. The objectives of this review are focused on role of cutting-edge nanotechnology-based strategies, such as lipid-based nanocarriers, i.e., lipid nanoparticles, microemulsions, nanoemulsions, liposomes, ethosomes, niosomes, transfersomes, aspasomes, invasomes penetration-enhancing vesicles; inorganic nanocarriers, i.e., gold nanoparticles and fullerenes; and polymer-based nanocarriers i.e., polymeric nanoparticles, polymerosomes, and polymeric micelles for the management of hyperpigmentation.

1. Introduction

Hyperpigmentation is attributed to melanocytes which generates excess amounts of melanin, which is subsequently captivated through keratinocytes and accumulated within dermis [1,2]. Melasma is a highly prevalent and globally recurrent disorder of hyperpigmentation. Melasma is derived from the Greek word “melas”, which means “black”, and refers to the clinical appearance of dark brownish spots. This disorder is also referred to as “chloasma”, which means “green in hue” [3]. Melasma involves symmetrically distributed pigmentation with sharply bordered light brown to bluish-grey patches and freckle like spot with uneven and spiky borders which develops gradually over weeks or years [4]. In wintertime, hypepigmentation patches gets often fade but appears worse in summer. Pigmentation might be in the form of spots, confetti, linear, or continuous lines. The three major patterns of pigmentation distribution include: (i) centro facial pattern, which has been observed in 65% of cases and affects cheeks, forehead, upper lip, and nose; (ii) malar pattern, which specifically affects the cheeks as well as nose and has been identified in 20% of cases; and (iii) mandibular pattern, which has been recognized in 15% of the cases and distinctively affects mandibular ramus [5,6]. Furthermore, melasma is most typically described in females in their twenties and thirties during their reproductive years. Melasma is uncommon in men, who account for less than 10% of all instances. It is rarely recorded before the age of adolescence. Melasma over extra-facial region is frequently observed in postmenopausal women [7]. The melasma is a photoageing condition in genetically susceptible people and has a detrimental influence on the patient’s quality of life [8]. The Fitzpatrick skin phototype classification system, life cycle of melanin, mechanism of action of anti-hyperpigmenting drugs, and pharmacotherapy strategies for the treatment of melasma are described in this review. The objectives of this review are focused on an overview of the role of lipid-based, inorganic, and polymer-based nanocarriers for the management of melasma. For this purpose, an extensive search of the literature was conducted using the Google Scholar, PubMed, and ScienceDirect databases from year 2000 to 2022.

2. Fitzpatrick Skin Phototype (FSPT) Classification System

With the help of light induced fluorescence, Wood’s light may be used to assess the depth of melanin. Based on the Wood’s light examination, melasma is divided into four clinical types, i.e., epidermal, dermal, dark-brown, and indeterminate or inapparent melasma. Epidermal melasma appears as light brown, and under Wood’s light, strong pigmentation is observed when melanin is spread across epidermal layers. The dermal melasma gets manifested as brown or blue grey colored patches under visible light along with a lot of pigmented cutaneous melanophages. In dark-brown melasma, Wood’s lamp light might promote pigmentation enhancement in certain regions while leaving others unchanged. Indeterminate or unapparent melasma mainly affects dark-brown skinned people [7,8,9]. The FSPT system was based upon the measurement of sun sensitivity and is specifically used to evaluate sunburn and suntan risk of patients. According to FSPT, individuals and races differ in their vulnerability to sunlight, as shown in Table 1 [8,10,11,12].

3. Life Cycle of Melanin

Hemoglobin, melanin, and carotene are the pigments which determine the skin color. The epidermal elements are involved in melanogenesis process which involves the production of melanin in melanosomes by melanocytes and gets deposited throughout epidermis [9,13,14]. Melanogenesis is induced through paracrine interaction between keratinocytes and melanocytes which expedite the release of melanogenic factors like pro-opiomelanocortin-derived peptides. The melanocyte present in epidermis stratum basale generates melanin and delivers to keratinocytes which subsequently combine, aggregates, and degrades resulting in change of skin color [15,16,17]. Melanocytes are skin pigmentation cells that contribute to melanin and have five stages during its lifecycle (Figure 1). Various compounds found in many skin care products have the potential to inhibit some of steps of melanin life cycle. Melanocytes generate melanin and subsequently transport melanin to the keratinocytes in epidermis. Melanin is produced when some proteins have been relocated and sorted to melanosomes [18]. The melanin generation is mediated through tyrosinase enzyme and pigmentation problems manifest in either of two ways, i.e., hyperpigmentation (rise in skin pigmentation) or hypopigmentation (decrease in skin pigmentation). Melasma (chloasma) and ephelides (freckles) are pigmentation disorders which are linked to skin pigmentation disturbances. Melasma can be caused by epidermal melanocyte hyperactivity which can lead to an increase in pigmentation [19,20,21,22,23].

4. Pharmacotherapy Approaches for Management of Hyperpigmentation

The primary crucial step in determining efficient and appropriate treatment for melasma patient is to determine the severity of melasma. Physical therapy with intense pulse light sources or lasers, chemical peels, dermabrasion, and microneedle technology are a few treatment strategies for melasma. Melasma can be treated with variety of topical and systemic drug administration. Oral therapies for the management of melasma include cyklokapron (tranexamic acid), glutathione, and polypodium aureum extract obtained from tropical fern leaves. Drugs, such as hydroquinone, kojic acid, azelaic acid, retinoic acid, flavonoids, arbutin, and ascorbic acid, are some examples which have potential activity for the topical therapy of hyperpigmentation [4]. Various photoprotective precautions include avoiding direct sun exposure and applying sunscreen on a regular basis should always be encouraged [9]. The mechanisms of action of drugs for management of hyperpigmentation via topical application are depicted in Figure 2.

5. Role of Lipid-Based Nanocarriers in Hyperpigmentation

Nanotechnology based treatment strategies have immense potential to improve therapeutic potential of anti-hyperpigmenting drugs for exclusive therapy of hyperpigmentation. The encapsulation of topical hypopigmenting drugs within nanocarriers-based delivery systems has been frequently explored recently for the effective management of melasma. These nanocarrier strategies have numerous advantages which include enhanced drug permeation, drug targeting, improved therapeutic potential, stability against degradation, as well as rapid and prolonged action [24,25]. A diagrammatic representation of various lipid based nanocarriers is depicted in Figure 3.

5.1. Lipid Nanoparticles

Lipid nanoparticles (LNPs) are novel pharmaceutical delivery systems which include nanostructured lipid carriers (NLCs) and solid lipid nanoparticles (SLNs) [26]. SLNs are spherical particles comprised of solid lipid having average diameter of 10–1000 nm and exists in solid state at ambient temperature [27]. NLCs are comprised of physiological and biocompatible solid lipid and liquid lipid, surfactants, and co-surfactants. NLCs have increased storage stability and loading capacity along with a reduced probability of drug leakage [28]. LNPs have potential applications in cosmetic and dermatological formulations, e.g., supporting improvements in skin elasticity, hydration, permeation, and drug targeting [29].

5.2. Microemulsion and Nanoemulsion

Microemulsions are homogenous, transparent, thermodynamic, and stable dispersions having droplet diameter in the range of 10–100 nm in which the surfactant coating serves as barrier between oil and water phases [30,31,32]. ME has capability to permeate hydrophilic as well as lipophilic drug molecules as liquid membrane carriers [33]. Microemulsion can increase the rate at which moisturizing chemicals or substances are transferred into skin. Microemulsion has the potential to facilitate the permeation of a drug into deeper skin layers by interrupting the stratum corneum lipid’s organized structure which results in loss of skin’s barrier characteristics which facilitates drug transport [34].
Nanoemulsion has been defined as an ultrafine homogeneous transparent or translucent oil-in-water or water-in-oil emulsion with mean droplet diameter ranging from 20 to 200 nm which has been stabilized by surfactants [35,36,37,38]. It can be prepared under high mechanical extrusion process through mixing oil phase with aqueous phase [39,40,41]. Nanoemulsion has potential to solubilize poorly soluble drugs and enhance the drug penetration across skin layers via topical administration [42,43].

5.3. Liposomes

Liposomes are lipid bilayer vesicles composed of phospholipids having 50–1000 nm diameter and serve as transport vehicles for physiologically active hydrophilic and lipophilic molecules [44,45]. These vesicular systems impart several advantages such as augmentation of drug’s solubility, bioavailability and stability. Furthermore, liposomes have great possibility for coupling with ligands to acquire active targeting to increase and maintain the therapeutic activity of drugs for prolonged period of time [45,46,47]. Liposomes are classified as small unilamellar vesicles (SUVs), large unilamellar vesicles (LUVs), and multilamellar vesicles (MLVs) with diameter of 100 nm, 200–800 nm, and 500–5000 nm, respectively [48]. Liposomes are good carriers for topical drug delivery because of their capability to prevent drug degradation and to encapsulate lipophilic as well as hydrophilic drugs. These also have strong affinity for keratin in skin’s horny layer and can penetrate deeper into skin. Liposomes tends to improve solubilization of poorly soluble drugs, act as permeation enhancer, have potential to produce local depot and tends to reduce adverse effects of drug [49,50]. Shigeta et al. found that the loading of linoleic acid into liposomes increased its solubility and hypopigmenting efficacy compared to non-liposomal preparations. Linoleic acid is adipose acids with concomitant inhibitory action on tyrosinase [51]. Another research study found that liposome production of anthocyanin (flavonoid with antioxidant and tyrosinase inhibitory properties) improved its photoprotective and antityrosinase activity in comparison to plain drug [52]. The encapsulations of Aloe vera extract (containing aloesin) into liposomes exhibited greater bioavailability and provided improved skin hypopigmenting activity as compared to pure extract [53]. Huh et al. described that the encapsulation of 4-n-butyl resorcinol into liposomes improved the stability and skin penetrability along with increase in tyrosinase inhibitory action to produce greater melanogenesis inhibitory effect [54]. Asparagus racemosus extract loaded liposomes suppressed the tyrosinase enzyme activity significantly in comparison to plain extract [55]. The liposomes production of phenylethyl resorcinol improved solubility, physical stability, and anti-tyrosinase action in comparison to plain drug [56]. Artocarpus lakoocha extract loaded liposomes exhibited improved skin penetration and skin whitening potential as compared to non-encapsulated extract [57]. In another investigation, it was found that the incorporation of arbutin into liposomes exhibited enhanced accumulation of arbutin in epidermis/dermis layers and improved the skin whitening potential [58].

5.4. Ethosomes

Ethosomes are comprised of a phospholipid bilayer membrane structure integrated with alcohol, polyglycol, and dihydrogen monooxide. These are ultra-deformable, soft, and flexible vesicular systems which have the potential to increase the permeation of bioactive into various layers of skin through topical application [59]. These vesicular systems have some additional advantages over traditional liposomes, e.g., drug penetration via epidermal layers, propensity to fluidize, and lower transition temperature of stratum corneum lipids, which could be attributable to the alcoholic content of ethosomes. Therefore, ethosomes have emerged as highly efficient drug delivery systems which have the capability to impart high drug diffusivity into deeper skin layers. It was revealed that ethosomes can increase phenylethyl resorcinol transmission across skin layers and form a drug depot inside skin with improved drug solubility and stability. It has higher inhibitory capability against tyrosinase than liposome-based formulations [60].

5.5. Niosomes

Niosomes are comprised of unilamellar or multilamellar vesicles made up of alkyl or dialkylpolyglycerol ethers with or without cholesterol having size range from 10–100 nm [61]. Niosomes are osmotically active vesicles with rigid membrane bilayer which offers several benefits as compared to conventional liposomes like cost effectiveness, greater chemical stability and prevention of drug leakage [61,62]. Numerous studies have reported that the topical delivery of niosomes has higher effectiveness owing to their capability to modify the drug withholding time in the stratum corneum and tendency to reduce systemic absorption [63]. The main ingredient of niosomes is nonionic surfactant which acts as permeation enhancer. The niosomes formulation of kojic acid and hydroquinone showed sustained drug delivery profiles [64]. The skin whitening effect of phenylethyl resorcinol was improved through niosomes based formulation due to an increase in skin penetration potential [65].

5.6. Transferosomes

Transferosomes are newly developed, elastic, and ultra-deformable vesicular systems comprised of phospholipids, water, surfactants, and a bilayer membrane softening components to enhance transdermal delivery [66]. These are highly deformable vesicles which contain edge activator like tween 80 or sodium deoxycholate in bilayer which have propensity to promote lipid bilayer flexibility and overcome obstacles to skin permeation by squeezing themselves easily across stratum corneum [67]. Linoleic acid was loaded into transferosomes which considerably improved its skin permeability in comparison to hydro-alcoholic solution [68]. Transferosomes loaded with phenylethyl resorcinol improved its solubility, stability, permeability, skin irritation, and tyrosinase inhibitory action as compared to liposomes [69]. In 2018, Limsuwan and his colleagues investigated that transferosomes demonstrated improved solubility and stability of phenylethyl resorcinol [70]. The niacinamide loaded transferosomes improved skin permeability, solubility, stability, and whitening efficacy in comparison to regular liposomes [71]. In another research, it was investigated whether arbutin-loaded transferosomes exhibited improved skin permeation and the deposition of hydrophilic skin-whitening compounds [72].

5.7. Aspasomes

Ascorbyl palmitate vesicles called aspasomes are composed of ascorbyl palmitate bilayer rather than phospholipids moieties present in conventional liposomes [73]. In addition, ascorbyl palmitate is an amphiphilic molecule having antioxidant action. The addition of magnesium ascorbyl phosphate to aspasomes tends to amplify epidermal permeation and retention in comparison to 15% trichloroacetic acid [74].

5.8. Invasomes

Invasomes are ethanol and terpene-containing vesicular systems which act as skin penetration boosters due to their capacity to disrupt the order of stratum corneum packing by assigning a net negative surface charge and inhibiting vesicle coalescence due to electrostatic repulsion force [75,76]. Terpenes are naturally occurring volatile oils that are usually regarded as a safe chemical with a minimal irritation risk at low doses (1–5%) and produce reversible influence on stratum corneum lipid deposition. It was discovered that ethanol and terpene produced a synergistic effect on percutaneous absorption [77]. A research study evaluated the transferosomes, invasomes, and conventional liposomes as skin permeation vesicular carriers of phenylethyl resorcinol and disclosed that invasomes exhibited deeper skin penetration which could be attributed to their greater deformability as compared to other two vesicles [78].

5.9. Penetration-Enhancing Vesicles

Penetration-enhancing vesicles (PEVs) are called absorption promoters and sorption accelerants due to presence of penetration enhancers into phospholipids bilayer [79]. PEVs are vesicular systems which have applications in improving drug penetration through the skin layers and function in similar fashion as edge activators in transferosomes [80]. PEVs, upon contact with skin keratin, tend to alter stratum corneum fluidity which ultimately results in an increase in drug partitioning across the stratum corneum [81]. The examples of penetration enhancers used in PEVs are fatty acids (e.g., stearic acid, lauric acid), capryl-caproyl macrogol 8-glyceride (Labrasol®), diethylene glycol monoethyl ether (Transcutol®), and ether alcohols (e.g., L-menthol, cineole and limonene) [82]. A group of researchers investigated the effects of lauroylcholine chloride and monoolein as penetration enhancer in the topical delivery of 3-hydroxycoumarin and revealed enhanced drug transportation to deeper skin layers [83].

6. Role of Inorganic Nanocarriers in Hyperpigmentation

The nanocarriers based on non-metal elements such as sulfur and diamonds are being studied for application in drug delivery for management of melasma [84]. The inorganic nanocarriers can be comprised of metal or non-metal element. The non-metal elements, e.g., diamond and sulfur, are contained within the core, while metals elements are contained inside shell and provides suitable substrate for conjugation with bio-macromolecules [85]. Inorganic nanocarriers offer superior mechanical strength, chemical stability, and controlled drug release across skin via topical drug delivery. The different types of inorganic nanocarriers are fullerenes, carbon nanotubes, iron oxide, gold nanoparticles, silver nanoparticles, and quantum dots [31].

6.1. Gold Nanoparticles

Gold nanoparticles (AuNPs) are small gold particles which have a high degree of stability when disseminated in water. AuNPs have characteristics, such as chemical inertness, excellent biological compatibility, and high stability [86]. In a research study, the efficacy of Panax ginseng leaves extract based AuNPs on tyrosinase activity, tyrosinase gene-expression, and cellular melanin concentration in murine melanoma B16BL6 cell lines was investigated. It was found that synthesized AuNPs have the potential to limit the activity of tyrosinase in B16 cells stimulated by melanocyte-stimulating hormone and suppress tyrosinase at transcriptional level in comparison to arbutin, which demonstrated their efficacy in skin whitening and depletion of melanin content [87].

6.2. Fullerenes

Fullerenes are spheroid ball-shaped nanoparticles with carbon structure. These are also called cylinder carbon nanotube C60 [33]. Their enormous interior capacity allows for the incorporation of bio-molecules and their outside surface can be chemically altered for topical drug delivery for management of skin disorders [88]. These are currently utilized in cosmetics as anti-aging, skin brightening, ultraviolet protection, and antioxidants for the prevention of melanogenesis progression [89]. The fullerene derivative encapsulated in hydrophilic polyvinylpyrrolidone dramatically reduced UVA-induced melanogenesis in normal human epidermal melanocytes in comparison to lascorbic acid and arbutin, which could be attributed to enhanced antityrosinase action [90].

7. Role of Polymer-Based Nanocarriers in Hyperpigmentation

Polymer-based nanocarriers are made up of biodegradable and biocompatible polymers with particle sizes ranging from 10 to 1000 nanometers [91,92]. The examples of natural polymers are chitosan, gelatin, alginate, and albumin. Synthetic biodegradable polymers include polylactide-co-glycolide and polycaprolactone, whereas synthetic non-biodegradable polymers include polymethylmethacrylate, polyacrylates and ethyl cellulose [93,94,95,96]. The polymer based nanocarriers explored for the management of hyperpigmentation include polymeric nanoparticles, polymerosomes, and polymeric micelles [97,98].

7.1. Polymeric Nanoparticles

The polymeric nanoparticles include either nanospheres or nanocapsules which represent a matrix or reservoir system, respectively [49]. These can be utilized for altering drug release profile, e.g., delayed release and controlled release, or their residence time in skin can be extended [99]. The drug release process from polymeric nanoparticles includes polymer swelling by hydration and drug release via diffusion, enzymatic cleavage, and drug desorption from polymeric systems [100]. The chitosan and ethyl cellulose based polymeric nanoparticles have been utilized for topical drug administration for the management of hyperpigmentation. Chitosan is a cationic, biocompatible, mucoadhesive, and FDA approved polymer for cutaneous drug delivery [101,102,103,104]. The surface coating of N-(2-hydroxyl) propyl-3-trimethyl ammonium chitosan chloride over liposomes effectively sequesters the permeability of kojic acid and data illustrated that melanin synthesis in skin was dramatically reduced in comparison to traditional liposome [105]. Ethyl cellulose is a synthetic, hydrophilic, and non-biodegradable polymer with the ability to synthesize films with excellent adherence [106]. In a research study, it was found that the incorporation of ascorbic acid into ethyl cellulose nanoparticles leads to an increase in its stability, skin diffusivity, and antityrosinase activity with improved skin whitening potential [107].

7.2. Polymerosomes

Polymerosomes are colloidal hollow nanospheres comprised of aqueous core and polymer-based bilayer membranes identical to lipid vesicular nanocarriers [108,109,110]. Polymerosomes have size ranging between 50 nm to 5 µm and the bilayer thickness of typical polymerosomes is approximately 10 nm, which is larger in comparison to the thickness of the lipid vesicular bilayer, which is approximately 4–5 nm [111].

7.3. Polymeric Micelles or Poloxamers

These core-shell nanocarriers have size range between 10 and 100 nm and have the potential to self-assemble. These are composed of amphiphilic graft copolymers generated in aqueous solutions [112]. The critical micelle concentration is the minimum concentration required by amphiphilic molecules to start micellization in order to produce polymeric micelles. The polymeric micelles have the capability to improve aqueous solubility, inhibit drug degradation, as well as increase skin hydration and drug permeability across skin layers [113]. A research study revealed that the loading of glabridin into amphiphilic cationic chitosan micelles leads to drug permeability enhancement via layers of skin and causes the inhibition of melanin production, which is required for the effective management of skin hyperpigmentation conditions [114].

8. Application of Nanocarriers for Management of Hyperpigmentation

The research outcomes from investigations based on nanocarriers, such as nanoemulsion, gold nanoparticles, nanospheres, dendrimers, cubosomes, carbon nanotubes, polymerosomes, liposomes, niosomes, solid lipid nanoparticles, and nanostructured lipid carrier, recently explored for topical drug delivery for the management of hyperpigmentation are compiled in Table 2.

9. Conclusions

Hyperpigmentation is primarily a dermatological facial ailment which manifests as a highly psychosocially relevant condition apparent as symmetrically distributed hyper-pigmented dark brown spots with serrated and irregular borders. The various outlines of pigmentation include centro-facial pattern, malar pattern, and mandibular pattern. The different factors which contribute to the development and progression of melasma include ultraviolet ray exposure, excessive application of cosmetics, photosensitizing drugs, hormonal therapy, and irregular synthesis of melanocyte stimulating hormone. This article conclusively manifested that nanotechnology-based approaches, e.g., lipid-based nanocarriers, inorganic nanocarriers, and polymer-based nanocarriers, emerge as cutting-edge technologies for encapsulating hypopigmenting molecules in order to increase their physicochemical strength and permeability into skin layers for the treatment of hyperpigmentation. The topical administration of hypopigmenting drugs based on nanotechnology could be utilized as a primary line of therapy along with the oral administration of additional therapy for the successful treatment of hyperpigmentation.

Author Contributions

Conceptualization, S.S., N.S., and T.B.; methodology, S.S. and I.Z.; investigation, S.S., T.B., and S.G.B.; resources, T.B. and S.G.B.; data curation, A.A. and I.Z.; writing—original draft preparation, S.S., N.S., and T.B.; writing—review and editing, S.S. and S.G.; visualization, M.K.A. and S.M.; supervision, T.B. and S.G.B. All authors have read and agreed to the published version of the manuscript.

Funding

Fundings for the publication of this paper are provided by University of Oradea, Oradea, Romania, by an Internal Project.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

The authors would like to thank Department of Pharmaceutics, MM College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana-Ambala, Haryana, India 133207 and School of Health Science, University of Petroleum and Energy Studies, Dehradun, Uttarakhand, India for providing facilities for the completion of this review. Fundings for the publication of this paper are provided by University of Oradea, Oradea, Romania, by an Internal Project is highly acknowledged.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

AuNPs Gold nanoparticles
FSPT Fitzpatrick Skin Phototype
LNPs Lipid nanoparticles
LUVs Large unilamellar vesicles
MASI Melasma area and severity index
MEs Microemulsions
MVVs Multivesicular vesicles
NEs Nanoemulsions
NLCs Nanostructured lipid carriers
PEVs Penetration enhancing vesicles
PMCP Partially myristoylated chitosan pyrrolidone carboxylate
SLNs Solid lipid nanoparticles
SUVs Small unilamellar vesicles

References

  1. Miot, L.D.B.; Miot, H.A.; da Silva, M.G.; Marques, M.E.A. Physiopathology of Melasma. An. Bras. Dermatol. 2009, 84, 623–635. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Ramos, P.M.; Miot, H.A. Female Pattern Hair Loss: A Clinical and Pathophysiological Review. An. Bras. Dermatol. 2015, 90, 529–543. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Grimes, P.E.; Ijaz, S.; Nashawati, R.; Kwak, D. New Oral and Topical Approaches for the Treatment of Melasma. Int. J. Women’s Dermatol. 2019, 5, 30–36. [Google Scholar] [CrossRef] [PubMed]
  4. Sarkar, R.; Puri, P.; Jain, R.K.; Singh, A.; Desai, A. Melasma in Men: A Clinical, Aetiological and Histological Study. J. Eur. Acad. Dermatol. Venereol. 2010, 24, 768–772. [Google Scholar] [CrossRef] [PubMed]
  5. Bagherani, N.; Gianfaldoni, S.; Smoller, B. An Overview on Melasma. Pigment. Disord. 2015, 2, 218. [Google Scholar]
  6. Katsambas, A.; Antoniou, C.H. Melasma. Classification and Treatment. J. Eur. Acad. Dermatol. Venereol. 1995, 4, 217–223. [Google Scholar] [CrossRef]
  7. Damevska, K. New Aspects of Melasma/Novi Aspekti Melazme. Serb. J. Dermatol. Venereol. 2014, 6, 5–18. [Google Scholar] [CrossRef] [Green Version]
  8. Lee, A.-Y. An Updated Review of Melasma Pathogenesis. Dermatol. Sin. 2014, 32, 233–239. [Google Scholar] [CrossRef] [Green Version]
  9. Hatem, S.; El Hoffy, N.M.; Elezaby, R.S.; Nasr, M.; Kamel, A.O.; Elkheshen, S.A. Background and Different Treatment Modalities for Melasma: Conventional and Nanotechnology-Based Approaches. J. Drug Deliv. Sci. Technol. 2020, 60, 101984. [Google Scholar] [CrossRef]
  10. Fitzpatrick, T.B. The Validity and Practicality of Sun-Reactive Skin Types I through VI. Arch. Dermatol. 1988, 124, 869–871. [Google Scholar] [CrossRef]
  11. Halder, R.M.; Nootheti, P.K. Ethnic Skin Disorders Overview. J. Am. Acad. Dermatol. 2003, 48, S143–S148. [Google Scholar] [CrossRef]
  12. Hexsel, D.; Lacerda, D.A.; Cavalcante, A.S.; Filho, C.A.S.M.; Kalil, C.L.P.V.; Ayres, E.L.; Azulay-Abulafia, L.; Weber, M.B.; Serra, M.S.; Lopes, N.F.P. Epidemiology of Melasma in B Razilian Patients: A Multicenter Study. Int. J. Dermatol. 2014, 53, 440–444. [Google Scholar] [CrossRef]
  13. Handel, A.C.; Miot, L.D.B.; Miot, H.A. Melasma: A Clinical and Epidemiological Review. An. Bras. Dermatol. 2014, 89, 771–782. [Google Scholar] [CrossRef]
  14. Videira, I.F.d.S.; Moura, D.F.L.; Magina, S. Mechanisms Regulating Melanogenesis. An. Bras. Dermatol. 2013, 88, 76–83. [Google Scholar] [CrossRef] [Green Version]
  15. Bandyopadhyay, D. Topical Treatment of Melasma. Indian J. Dermatol. 2009, 54, 303. [Google Scholar] [CrossRef]
  16. Boissy, R.E. Melanosome Transfer to and Translocation in the Keratinocyte. Exp. Dermatol. 2003, 12, 5–12. [Google Scholar] [CrossRef]
  17. Victor, F.C.; Gelber, J.; Rao, B. Melasma: A Review. J. Cutan. Med. Surg. Inc. Med. Surg. Dermatol. 2004, 8, 97–102. [Google Scholar] [CrossRef]
  18. Milette, F. Review of The Pigmentary System: Physiology and Pathophysiology by James J. Nordlund, Raymond E. Boissy, Vincent J. Hearing; et al. Dermatol. Pract. Concept. 2014, 4, 89. [Google Scholar] [CrossRef] [Green Version]
  19. Espósito, A.C.C.; Cassiano, D.P.; da Silva, C.N.; Lima, P.B.; Dias, J.A.F.; Hassun, K.; Bagatin, E.; Miot, L.D.B.; Miot, H.A. Update on Melasma—Part I: Pathogenesis. Dermatol. Ther. (Heidelb). 2022, 12, 1967–1988. [Google Scholar] [CrossRef]
  20. Lee, A. Recent Progress in Melasma Pathogenesis. Pigment Cell Melanoma Res. 2015, 28, 648–660. [Google Scholar] [CrossRef]
  21. Mohiuddin, A.K. Skin Lightening & Management of Hyperpigmentation. Int. J. Res. Biol. Pharm. 2019, 2, 1–37. [Google Scholar]
  22. Nii, D.; Espósito, A.C.; Peres, G.; Schmitt, J.V.; Miot, H. Tinted Sunscreens Lead to a Smaller Amount of the Product Applied on the Face. Int. J. Dermatol. 2020, 59, e438–e439. [Google Scholar] [CrossRef] [PubMed]
  23. Virador, V.; Matsunaga, N.; Matsunaga, J.; Valencia, J.; Oldham, R.J.; Kameyama, K.; Peck, G.L.; Ferrans, V.J.; Vieira, W.D.; Abdel-Malek, Z.A. Production of Melanocyte-specific Antibodies to Human Melanosomal Proteins: Expression Patterns in Normal Human Skin and in Cutaneous Pigmented Lesions. Pigment Cell Res. 2001, 14, 289–297. [Google Scholar] [CrossRef] [PubMed]
  24. El-Kayal, M.; Nasr, M.; Elkheshen, S.; Mortada, N. Colloidal (-)-Epigallocatechin-3-Gallate Vesicular Systems for Prevention and Treatment of Skin Cancer: A Comprehensive Experimental Study with Preclinical Investigation. Eur. J. Pharm. Sci. 2019, 137, 104972. [Google Scholar] [CrossRef] [PubMed]
  25. Shaaban, M.; Nasr, M.; Tawfik, A.A.; Fadel, M.; Sammour, O. Novel Bergamot Oil Nanospanlastics Combined with PUVB Therapy as a Clinically Translatable Approach for Vitiligo Treatment. Drug Deliv. Transl. Res. 2019, 9, 1106–1116. [Google Scholar] [CrossRef]
  26. Bseiso, E.A.; Nasr, M.; Sammour, O.; Abd El Gawad, N.A. Recent Advances in Topical Formulation Carriers of Antifungal Agents. Indian J. Dermatol. Venereol. Leprol. 2015, 81, 457. [Google Scholar] [CrossRef]
  27. Hanumanaik, M.; Patel, S.K.; Sree, K.R. Solid Lipid Nanoparticles: A Review. Int. J. Pharm. Sci. Res. 2013, 4, 928–940. [Google Scholar]
  28. Amer, S.S.; Nasr, M.; Mamdouh, W.; Sammour, O. Insights on the Use of Nanocarriers for Acne Alleviation. Curr. Drug Deliv. 2019, 16, 18–25. [Google Scholar] [CrossRef]
  29. Hajare, A.A.; Mali, S.S.; Ahir, A.A.; Thorat, J.D.; Salunkhe, S.S.; Nadaf, S.J.; Bhatia, N.M.; Chitranagari, K. Lipid Nanoparticles: A Modern Formulation Approach in Topical Drug Delivery Systems. J. Adv. Drug Deliv. 2014, 1, 30–37. [Google Scholar]
  30. Abu-Azzam, O.; Nasr, M. In Vitro Anti-Inflammatory Potential of Phloretin Microemulsion as a New Formulation for Prospective Treatment of Vaginitis. Pharm. Dev. Technol. 2020, 25, 930–935. [Google Scholar] [CrossRef]
  31. Al-Karaki, R.; Awadallah, A.; Tawfeek, H.M.; Nasr, M. Preparation, Characterization and Cytotoxic Activity of New Oleuropein Microemulsion against HCT-116 Colon Cancer Cells. Pharm. Chem. J. 2020, 53, 1118–1121. [Google Scholar] [CrossRef]
  32. Ramez, S.A.; Soliman, M.M.; Fadel, M.; Nour El-Deen, F.; Nasr, M.; Youness, E.R.; Aboel-Fadl, D.M. Novel Methotrexate Soft Nanocarrier/Fractional Erbium YAG Laser Combination for Clinical Treatment of Plaque Psoriasis. Artif. Cells Nanomed. Biotechnol. 2018, 46, 996–1002. [Google Scholar] [CrossRef]
  33. Nasr, M.; Abdel-Hamid, S.; Moftah, N.H.; Fadel, M.; Alyoussef, A.A. Jojoba Oil Soft Colloidal Nanocarrier of a Synthetic Retinoid: Preparation, Characterization and Clinical Efficacy in Psoriatic Patients. Curr. Drug Deliv. 2017, 14, 426–432. [Google Scholar] [CrossRef]
  34. Badawi, A.A.; Nour, S.A.; Sakran, W.S.; El-Mancy, S.M.S. Preparation and Evaluation of Microemulsion Systems Containing Salicylic Acid. AAPS Pharmscitech 2009, 10, 1081–1084. [Google Scholar] [CrossRef]
  35. Mahdi, Z.H.; Maraie, N.K. Overview on Nanoemulsion as a Recently Developed Approach in Drug Nanoformulation. Res. J. Pharm. Technol. 2019, 12, 5554–5560. [Google Scholar] [CrossRef]
  36. Shaker, D.S.; Ishak, R.A.H.; Ghoneim, A.; Elhuoni, M.A. Nanoemulsion: A Review on Mechanisms for the Transdermal Delivery of Hydrophobic and Hydrophilic Drugs. Sci. Pharm. 2019, 87, 17. [Google Scholar] [CrossRef] [Green Version]
  37. Kim, K.-T.; Kim, M.-H.; Park, J.-H.; Lee, J.-Y.; Cho, H.-J.; Yoon, I.-S.; Kim, D.-D. Microemulsion-Based Hydrogels for Enhancing Epidermal/Dermal Deposition of Topically Administered 20 (S)-Protopanaxadiol: In Vitro and in Vivo Evaluation Studies. J. Ginseng. Res. 2018, 42, 512–523. [Google Scholar] [CrossRef]
  38. Lovelyn, C. Current State of Nanoemulsions in Drug Delivery. J. Biomater. Nanobiotechnol. 2011, 2, 626–639. [Google Scholar] [CrossRef] [Green Version]
  39. Gupta, A.; Eral, H.B.; Hatton, T.A.; Doyle, P.S. Nanoemulsions: Formation, Properties and Applications. Soft Matter 2016, 12, 2826–2841. [Google Scholar] [CrossRef] [Green Version]
  40. Ismail, A.; Nasr, M.; Sammour, O. Nanoemulsion as a Feasible and Biocompatible Carrier for Ocular Delivery of Travoprost: Improved Pharmacokinetic/Pharmacodynamic Properties. Int. J. Pharm. 2020, 583, 119402. [Google Scholar] [CrossRef]
  41. Parthasarathi, S.; Muthukumar, S.P.; Anandharamakrishnan, C. The Influence of Droplet Size on the Stability, in Vivo Digestion, and Oral Bioavailability of Vitamin E Emulsions. Food Funct. 2016, 7, 2294–2302. [Google Scholar] [CrossRef] [PubMed]
  42. Aboofazeli, R. Nanometric-Scaled Emulsions (Nanoemulsions). Iran. J. Pharm. Res. IJPR 2010, 9, 325. [Google Scholar] [PubMed]
  43. Hatem, S.; Nasr, M.; Moftah, N.H.; Ragai, M.H.; Geneidi, A.S.; Elkheshen, S.A. Melatonin Vitamin C-Based Nanovesicles for Treatment of Androgenic Alopecia: Design, Characterization and Clinical Appraisal. Eur. J. Pharm. Sci. 2018, 122, 246–253. [Google Scholar] [CrossRef] [PubMed]
  44. Tokudome, Y.; Nakamura, K.; Itaya, Y.; Hashimoto, F. Enhancement of Skin Penetration of Hydrophilic and Lipophilic Compounds by PH-Sensitive Liposomes. J. Pharm. Pharm. Sci. 2015, 18, 249–257. [Google Scholar] [CrossRef] [PubMed]
  45. Upputuri, R.T.P.; Mandal, A.K.A. Sustained Release of Green Tea Polyphenols from Liposomal Nanoparticles; Release Kinetics and Mathematical Modelling. Iran. J. Biotechnol. 2017, 15, 277. [Google Scholar] [CrossRef] [Green Version]
  46. Chountoulesi, M.; Naziris, N.; Pippa, N.; Demetzos, C. The Significance of Drug-to-Lipid Ratio to the Development of Optimized Liposomal Formulation. J. Liposome Res. 2018, 28, 249–258. [Google Scholar] [CrossRef]
  47. Yadav, D.; Sandeep, K.; Pandey, D.; Dutta, R.K. Liposomes for Drug Delivery. J. Biotechnol. Biomater. 2017, 7. [Google Scholar] [CrossRef]
  48. Torchilin, V.P. Recent Advances with Liposomes as Pharmaceutical Carriers. Nat. Rev. Drug Discov. 2005, 4, 145–160. [Google Scholar] [CrossRef]
  49. Banihashemi, M.; Zabolinejad, N.; Jaafari, M.R.; Salehi, M.; Jabari, A. Comparison of Therapeutic Effects of Liposomal Tranexamic Acid and Conventional Hydroquinone on Melasma. J. Cosmet. Dermatol. 2015, 14, 174–177. [Google Scholar] [CrossRef]
  50. Taghavi, F.; Banihashemi, M.; Zabolinejad, N.; Salehi, M.; Jaafari, M.R.; Marhamati, H.; Golnouri, F.; Dorri, M. Comparison of Therapeutic Effects of Conventional and Liposomal Form of 4% Topical Hydroquinone in Patients with Melasma. J. Cosmet. Dermatol. 2019, 18, 870–873. [Google Scholar] [CrossRef]
  51. Shigeta, Y.; Imanaka, H.; Ando, H.; Ryu, A.; Oku, N.; Baba, N.; Makino, T. Skin Whitening Effect of Linoleic Acid Is Enhanced by Liposomal Formulations. Biol. Pharm. Bull. 2004, 27, 591–594. [Google Scholar] [CrossRef] [Green Version]
  52. Hwang, J.-M.; Kuo, H.-C.; Lin, C.-T.; Kao, E.-S. Inhibitory Effect of Liposome-Encapsulated Anthocyanin on Melanogenesis in Human Melanocytes. Pharm. Biol. 2013, 51, 941–947. [Google Scholar] [CrossRef]
  53. Ghafarzadeh, M.; Eatemadi, A. Clinical Efficacy of Liposome-Encapsulated Aloe Vera on Melasma Treatment during Pregnancy. J. Cosmet. Laser Ther. 2017, 19, 181–187. [Google Scholar] [CrossRef]
  54. Huh, S.Y.; SHIN, J.; NA, J.; HUH, C.; YOUN, S.; PARK, K. Efficacy and Safety of Liposome-encapsulated 4-n-butylresorcinol 0.1% Cream for the Treatment of Melasma: A Randomized Controlled Split-face Trial. J. Dermatol. 2010, 37, 311–315. [Google Scholar] [CrossRef]
  55. Fan, H.; Li, Y.; Huang, Y.; Liu, G.; Xia, Q. Preparation and Evaluation of Phenylethyl Resorcinol Liposome. Integr. Ferroelectr. 2014, 151, 89–98. [Google Scholar] [CrossRef]
  56. Therdphapiyanak, N.; Jaturanpinyo, M.; Waranuch, N.; Kongkaneramit, L.; Sarisuta, N. Development and Assessment of Tyrosinase Inhibitory Activity of Liposomes of Asparagus Racemosus Extracts. Asian J. Pharm. Sci. 2013, 8, 134–142. [Google Scholar] [CrossRef] [Green Version]
  57. Panichakul, T.; Rodboon, T.; Suwannalert, P.; Tripetch, C.; Rungruang, R.; Boohuad, N.; Youdee, P. Additive Effect of a Combination of Artocarpus Lakoocha and Glycyrrhiza Glabra Extracts on Tyrosinase Inhibition in Melanoma B16 Cells. Pharmaceuticals 2020, 13, 310. [Google Scholar] [CrossRef]
  58. Wen, A.-H.; Choi, M.-K.; Kim, D.-D. Formulation of Liposome for Topical Delivery of Arbutin. Arch. Pharm. Res. 2006, 29, 1187–1192. [Google Scholar] [CrossRef]
  59. Godin, B.; Touitou, E. Ethosomes: New Prospects in Transdermal Delivery. Crit. Rev. Ther. Drug Carr. Syst. 2003, 20. [Google Scholar] [CrossRef]
  60. Limsuwan, T.; Boonme, P.; Khongkow, P.; Amnuaikit, T. Ethosomes of Phenylethyl Resorcinol as Vesicular Delivery System for Skin Lightening Applications. Biomed Res. Int. 2017, 2017, 8310979. [Google Scholar] [CrossRef] [Green Version]
  61. Hunter, C.A.; Dolan, T.F.; Coombs, G.H.; Baillie, A.J. Vesicular Systems (Niosomes and Liposomes) for Delivery of Sodium Stibogluconate in Experimental Murine Visceral Leishmaniasis. J. Pharm. Pharmacol. 1988, 40, 161–165. [Google Scholar] [CrossRef] [PubMed]
  62. Atrux-Tallau, N.; Denis, A.; Padois, K.; Bertholle, V.; Huynh, T.T.N.; Haftek, M.; Falson, F.; Pirot, F. Skin Absorption Modulation: Innovative Non-Hazardous Technologies for Topical Formulations. Open Dermatol. J. 2010, 4, 3–9. [Google Scholar] [CrossRef] [Green Version]
  63. Mbah, C.C.; Attama, A.A. Vesicular Carriers as Innovative Nanodrug Delivery Formulations. In Organic Materials as Smart Nanocarriers for Drug Delivery; Elsevier: Amsterdam, The Netherlands, 2018; pp. 519–559. [Google Scholar]
  64. Divanbeygikermani, M.; Pardakhty, A.; Amanatfard, A. Kojic Acid and Hydroquinone Non-Ionic Surfactant Vesicles for Topical Application. Int. Pharm. Acta 2018, 1, 110. [Google Scholar]
  65. Buruschat, J.; Amnuaikit, T. Preparation of Phenylethyl Resorcinol Niosomes for Cosmetic Formulation: Effects of BrijTM72 and Cholesterol. Lat. Am. J. Pharm. 2016, 35, 1640–1644. [Google Scholar]
  66. Fadel, M.; Samy, N.; Nasr, M.; Alyoussef, A.A. Topical Colloidal Indocyanine Green-Mediated Photodynamic Therapy for Treatment of Basal Cell Carcinoma. Pharm. Dev. Technol. 2017, 22, 545–550. [Google Scholar] [CrossRef]
  67. Kameyama, K.; Sakai, C.; Kondoh, S.; Yonemoto, K.; Nishiyama, S.; Tagawa, M.; Murata, T.; Ohnuma, T.; Quigley, J.; Dorsky, A. Inhibitory Effect of Magnesium L-Ascorbyl-2-Phosphate (VC-PMG) on Melanogenesis in Vitro and in Vivo. J. Am. Acad. Dermatol. 1996, 34, 29–33. [Google Scholar] [CrossRef]
  68. Celia, C.; Cilurzo, F.; Trapasso, E.; Cosco, D.; Fresta, M.; Paolino, D. Ethosomes® and Transfersomes® Containing Linoleic Acid: Physicochemical and Technological Features of Topical Drug Delivery Carriers for the Potential Treatment of Melasma Disorders. Biomed. Microdevices 2012, 14, 119–130. [Google Scholar] [CrossRef]
  69. Amnuaikit, T.; Limsuwan, T.; Khongkow, P.; Boonme, P. Vesicular Carriers Containing Phenylethyl Resorcinol for Topical Delivery System; Liposomes, Transfersomes and Invasomes. Asian J. Pharm. Sci. 2018, 13, 472–484. [Google Scholar] [CrossRef]
  70. Limsuwan, T.; Boonme, P.; Amnuaikit, T. Enhanced Stability of Phenylethyl Resorcinol in Elastic Vesicular Formulations. Trop. J. Pharm. Res. 2018, 17, 1895–1902. [Google Scholar] [CrossRef]
  71. Lee, M.-H.; Lee, K.-K.; Park, M.-H.; Hyun, S.-S.; Kahn, S.-Y.; Joo, K.-S.; Kang, H.-C.; Kwon, W.-T. In Vivo Anti-Melanogenesis Activity and in Vitro Skin Permeability of Niacinamide-Loaded Flexible Liposomes (BounsphereTM). J. Drug Deliv. Sci. Technol. 2016, 31, 147–152. [Google Scholar] [CrossRef]
  72. Bian, S.; Choi, M.-K.; Lin, H.; Zheng, J.; Chung, S.-J.; Shim, C.-K.; Kim, D.-D. Deformable Liposomes for Topical Skin Delivery of Arbutin. J. Pharm. Investig. 2006, 36, 299–304. [Google Scholar]
  73. Amer, S.S.; Nasr, M.; Abdel-Aziz, R.T.A.; Moftah, N.H.; El Shaer, A.; Polycarpou, E.; Mamdouh, W.; Sammour, O. Cosm-Nutraceutical Nanovesicles for Acne Treatment: Physicochemical Characterization and Exploratory Clinical Experimentation. Int. J. Pharm. 2020, 577, 119092. [Google Scholar] [CrossRef]
  74. Aboul-Einien, M.H.; Kandil, S.M.; Abdou, E.M.; Diab, H.M.; Zaki, M.S.E. Ascorbic Acid Derivative-Loaded Modified Aspasomes: Formulation, in Vitro, Ex Vivo and Clinical Evaluation for Melasma Treatment. J. Liposome Res. 2020, 30, 54–67. [Google Scholar] [CrossRef]
  75. El-Nabarawi, M.A.; Shamma, R.N.; Farouk, F.; Nasralla, S.M. Dapsone-Loaded Invasomes as a Potential Treatment of Acne: Preparation, Characterization, and in Vivo Skin Deposition Assay. Aaps Pharmscitech 2018, 19, 2174–2184. [Google Scholar] [CrossRef]
  76. Paolino, D.; Lucania, G.; Mardente, D.; Alhaique, F.; Fresta, M. Ethosomes for Skin Delivery of Ammonium Glycyrrhizinate: In Vitro Percutaneous Permeation through Human Skin and in Vivo Anti-Inflammatory Activity on Human Volunteers. J. Control. Release 2005, 106, 99–110. [Google Scholar] [CrossRef]
  77. Dragicevic-Curic, N.; Scheglmann, D.; Albrecht, V.; Fahr, A. Temoporfin-Loaded Invasomes: Development, Characterization and in Vitro Skin Penetration Studies. J. Control. Release 2008, 127, 59–69. [Google Scholar] [CrossRef]
  78. Shah, S.M.; Ashtikar, M.; Jain, A.S.; Makhija, D.T.; Nikam, Y.; Gude, R.P.; Steiniger, F.; Jagtap, A.A.; Nagarsenker, M.S.; Fahr, A. LeciPlex, Invasomes, and Liposomes: A Skin Penetration Study. Int. J. Pharm. 2015, 490, 391–403. [Google Scholar] [CrossRef]
  79. Manconi, M.; Caddeo, C.; Sinico, C.; Valenti, D.; Mostallino, M.C.; Lampis, S.; Monduzzi, M.; Fadda, A.M. Penetration Enhancer-Containing Vesicles: Composition Dependence of Structural Features and Skin Penetration Ability. Eur. J. Pharm. Biopharm. 2012, 82, 352–359. [Google Scholar] [CrossRef]
  80. Aldalaen, S.; Nasr, M.; El-Gogary, R.I. Angiogenesis and Collagen Promoting Nutraceutical-Loaded Nanovesicles for Wound Healing. J. Drug Deliv. Sci. Technol. 2020, 56, 101548. [Google Scholar] [CrossRef]
  81. Kapoor, A.; Mishra, S.K.; Verma, D.K.; Pandey, P. Chemical Penetration Enhancers for Transdermal Drug Delivery System. J. Drug Deliv. Ther. 2018, 8, 62–66. [Google Scholar] [CrossRef]
  82. Bsieso, E.A.; Nasr, M.; Moftah, N.H.; Sammour, O.A.; Abd El Gawad, N.A. Could Nanovesicles Containing a Penetration Enhancer Clinically Improve the Therapeutic Outcome in Skin Fungal Diseases? Nanomedicine 2015, 10, 2017–2031. [Google Scholar] [CrossRef] [PubMed]
  83. Schlich, M.; Fornasier, M.; Nieddu, M.; Sinico, C.; Murgia, S.; Rescigno, A. 3-Hydroxycoumarin Loaded Vesicles for Recombinant Human Tyrosinase Inhibition in Topical Applications. Colloids Surf. B Biointerfaces 2018, 171, 675–681. [Google Scholar] [CrossRef] [PubMed]
  84. Pugazhendhi, A.; Edison, T.N.J.I.; Karuppusamy, I.; Kathirvel, B. Inorganic Nanoparticles: A Potential Cancer Therapy for Human Welfare. Int. J. Pharm. 2018, 539, 104–111. [Google Scholar] [CrossRef] [PubMed]
  85. Swierczewska, M.; Lee, S.; Chen, X. Inorganic Nanoparticles for Multimodal Molecular Imaging. Mol. Imaging 2011, 10, 2011–7290. [Google Scholar] [CrossRef]
  86. Khodakiya, A.S.; Chavada, J.R.; Jivani, N.P.; Patel, B.N.; Khodakiya, M.S.; Ramoliya, A.P. Microemulsions as Enhanced Drug Delivery Carrier: An Overview. Am. J. Pharmtech. Res. 2012, 206–226. [Google Scholar]
  87. Jiménez-Pérez, Z.E.; Singh, P.; Kim, Y.-J.; Mathiyalagan, R.; Kim, D.-H.; Lee, M.H.; Yang, D.C. Applications of Panax Ginseng Leaves-Mediated Gold Nanoparticles in Cosmetics Relation to Antioxidant, Moisture Retention, and Whitening Effect on B16BL6 Cells. J. Ginseng Res. 2018, 42, 327–333. [Google Scholar] [CrossRef]
  88. Koo, O.M.; Rubinstein, I.; Onyuksel, H. Role of Nanotechnology in Targeted Drug Delivery and Imaging: A Concise Review. Nanomed. Nanotechnol. Biol. Med. 2005, 1, 193–212. [Google Scholar] [CrossRef]
  89. Elnaggar, Y.S.R.; El-Refaie, W.M.; El-Massik, M.A.; Abdallah, O.Y. Lecithin-Based Nanostructured Gels for Skin Delivery: An Update on State of Art and Recent Applications. J. Control. Release 2014, 180, 10–24. [Google Scholar] [CrossRef]
  90. Xiao, L.; Matsubayashi, K.; Miwa, N. Inhibitory Effect of the Water-Soluble Polymer-Wrapped Derivative of Fullerene on UVA-Induced Melanogenesis via Downregulation of Tyrosinase Expression in Human Melanocytes and Skin Tissues. Arch. Dermatol. Res. 2007, 299, 245–257. [Google Scholar] [CrossRef]
  91. Das, S.S.; Bharadwaj, P.; Bilal, M.; Barani, M.; Rahdar, A.; Taboada, P.; Bungau, S.; Kyzas, G.Z. Stimuli-Responsive Polymeric Nanocarriers for Drug Delivery, Imaging, and Theragnosis. Polymers 2020, 12, 1397. [Google Scholar] [CrossRef]
  92. Rangari, A.T.; Ravikumar, P. Polymeric Nanoparticles Based Topical Drug Delivery: An Overview. Asian J. Biomed. Pharm. Sci. 2015, 5, 5. [Google Scholar] [CrossRef]
  93. Samadzadeh, S.; Mousazadeh, H.; Ghareghomi, S.; Dadashpour, M.; Babazadeh, M.; Zarghami, N. In Vitro Anticancer Efficacy of Metformin-Loaded PLGA Nanofibers towards the Post-Surgical Therapy of Lung Cancer. J. Drug Deliv. Sci. Technol. 2021, 61, 102318. [Google Scholar] [CrossRef]
  94. Mogheri, F.; Jokar, E.; Afshin, R.; Akbari, A.A.; Dadashpour, M.; Firouzi-amandi, A.; Serati-Nouri, H.; Zarghami, N. Co-Delivery of Metformin and Silibinin in Dual-Drug Loaded Nanoparticles Synergistically Improves Chemotherapy in Human Non-Small Cell Lung Cancer A549 Cells. J. Drug Deliv. Sci. Technol. 2021, 66, 102752. [Google Scholar] [CrossRef]
  95. Amirsaadat, S.; Jafari-Gharabaghlou, D.; Alijani, S.; Mousazadeh, H.; Dadashpour, M.; Zarghami, N. Metformin and Silibinin Co-Loaded PLGA-PEG Nanoparticles for Effective Combination Therapy against Human Breast Cancer Cells. J. Drug Deliv. Sci. Technol. 2021, 61, 102107. [Google Scholar] [CrossRef]
  96. Adlravan, E.; Nejati, K.; Karimi, M.A.; Mousazadeh, H.; Abbasi, A.; Dadashpour, M. Potential Activity of Free and PLGA/PEG Nanoencapsulated Nasturtium Officinale Extract in Inducing Cytotoxicity and Apoptosis in Human Lung Carcinoma A549 Cells. J. Drug Deliv. Sci. Technol. 2021, 61, 102256. [Google Scholar] [CrossRef]
  97. Lombardo, D.; Kiselev, M.A.; Caccamo, M.T. Smart Nanoparticles for Drug Delivery Application: Development of Versatile Nanocarrier Platforms in Biotechnology and Nanomedicine. J. Nanomater. 2019, 2019, 3702518. [Google Scholar] [CrossRef]
  98. Tong, R.; Cheng, J. Anticancer Polymeric Nanomedicines. J. Macromol. Sci. Part C Polym. Rev. 2007, 47, 345–381. [Google Scholar] [CrossRef]
  99. Guterres, S.S.; Alves, M.P.; Pohlmann, A.R. Polymeric Nanoparticles, Nanospheres and Nanocapsules, for Cutaneous Applications. Drug Target Insights 2007, 2, 117739280700200000. [Google Scholar] [CrossRef]
  100. Singh, R.; Lillard Jr, J.W. Nanoparticle-Based Targeted Drug Delivery. Exp. Mol. Pathol. 2009, 86, 215–223. [Google Scholar] [CrossRef] [Green Version]
  101. Abd-Allah, H.; Abdel-Aziz, R.T.A.; Nasr, M. Chitosan Nanoparticles Making Their Way to Clinical Practice: A Feasibility Study on Their Topical Use for Acne Treatment. Int. J. Biol. Macromol. 2020, 156, 262–270. [Google Scholar] [CrossRef]
  102. Ayumi, N.S.; Sahudin, S.; Hussain, Z.; Hussain, M.; Samah, N.H.A. Polymeric Nanoparticles for Topical Delivery of Alpha and Beta Arbutin: Preparation and Characterization. Drug Deliv. Transl. Res. 2019, 9, 482–496. [Google Scholar] [CrossRef] [PubMed]
  103. Mohammed, M.A.; Syeda, J.T.M.; Wasan, K.M.; Wasan, E.K. An Overview of Chitosan Nanoparticles and Its Application in Non-Parenteral Drug Delivery. Pharmaceutics 2017, 9, 53. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  104. Park, Y.-S.; Park, H.-J.; Lee, J. Stabilization of Glabridin by Chitosan Nano-Complex. J. Korean Soc. Appl. Biol. Chem. 2012, 55, 457–462. [Google Scholar] [CrossRef]
  105. Wang, Y.-W.; Jou, C.-H.; Hung, C.-C.; Yang, M.-C. Cellular Fusion and Whitening Effect of a Chitosan Derivative Coated Liposome. Colloids Surf. B Biointerfaces 2012, 90, 169–176. [Google Scholar] [CrossRef] [PubMed]
  106. Urbán-Morlán, Z.; Mendoza-Elvira, S.E.; Hernández-Cerón, R.S.; Alcalá-Alcalá, S.; Ramírez-Mendoza, H.; Ciprián-Carrasco, A.; Piñón-Segundo, E.; Quintanar-Guerrero, D. Preparation of Ethyl Cellulose Nanoparticles by Solvent-Displacement Using the Conventional Method and a Recirculation System. J. Mex. Chem. Soc. 2015, 59, 173–180. [Google Scholar] [CrossRef]
  107. Duarah, S.; Durai, R.D.; Narayanan, V.B. Nanoparticle-in-Gel System for Delivery of Vitamin C for Topical Application. Drug Deliv. Transl. Res. 2017, 7, 750–760. [Google Scholar] [CrossRef]
  108. Cho, H.K.; Cheong, I.W.; Lee, J.M.; Kim, J.H. Polymeric Nanoparticles, Micelles and Polymersomes from Amphiphilic Block Copolymer. Korean J. Chem. Eng. 2010, 27, 731–740. [Google Scholar] [CrossRef]
  109. Lee, J.S.; Feijen, J. Polymersomes for Drug Delivery: Design, Formation and Characterization. J. Control. Release 2012, 161, 473–483. [Google Scholar] [CrossRef]
  110. Zhang, X.; Zhang, P. Polymersomes in Nanomedicine-A Review. Curr. Nanosci. 2017, 13, 124–129. [Google Scholar] [CrossRef] [Green Version]
  111. Mabrouk, E.; Cuvelier, D.; Pontani, L.-L.; Xu, B.; Lévy, D.; Keller, P.; Brochard-Wyart, F.; Nassoy, P.; Li, M.-H. Formation and Material Properties of Giant Liquid Crystal Polymersomes. Soft Matter 2009, 5, 1870–1878. [Google Scholar] [CrossRef]
  112. Riess, G. Micellization of Block Copolymers. Prog. Polym. Sci. 2003, 28, 1107–1170. [Google Scholar] [CrossRef] [Green Version]
  113. Xu, W.; Ling, P.; Zhang, T. Polymeric Micelles, a Promising Drug Delivery System to Enhance Bioavailability of Poorly Water-Soluble Drugs. J. Drug Deliv. 2013, 2013, 340315. [Google Scholar] [CrossRef]
  114. Seino, H.; Arai, Y.; Nagao, N.; Ozawa, N.; Hamada, K. Efficient Percutaneous Delivery of the Antimelanogenic Agent Glabridin Using Cationic Amphiphilic Chitosan Micelles. PLoS ONE 2016, 11, e0164061. [Google Scholar] [CrossRef]
  115. Khezri, K.; Saeedi, M.; Morteza-Semnani, K.; Akbari, J.; Rostamkalaei, S.S. An Emerging Technology in Lipid Research for Targeting Hydrophilic Drugs to the Skin in the Treatment of Hyperpigmentation Disorders: Kojic Acid-Solid Lipid Nanoparticles. Artif. Cells Nanomed. Biotechnol. 2020, 48, 841–853. [Google Scholar] [CrossRef]
  116. Sanna, V.; Gavini, E.; Cossu, M.; Rassu, G.; Giunchedi, P. Solid Lipid Nanoparticles (SLN) as Carriers for the Topical Delivery of Econazole Nitrate: In-Vitro Characterization, Ex-Vivo and in-Vivo Studies. J. Pharm. Pharmacol. 2007, 59, 1057–1064. [Google Scholar] [CrossRef]
  117. Bhalekar, M.R.; Pokharkar, V.; Madgulkar, A.; Patil, N.; Patil, N. Preparation and Evaluation of Miconazole Nitrate-Loaded Solid Lipid Nanoparticles for Topical Delivery. Aaps Pharmscitech 2009, 10, 289–296. [Google Scholar] [CrossRef] [Green Version]
  118. Marto, J.; Sangalli, C.; Capra, P.; Perugini, P.; Ascenso, A.; Gonçalves, L.; Ribeiro, H. Development and Characterization of New and Scalable Topical Formulations Containing N-Acetyl-d-Glucosamine-Loaded Solid Lipid Nanoparticles. Drug Dev. Ind. Pharm. 2017, 43, 1792–1800. [Google Scholar] [CrossRef]
  119. Ghanbarzadeh, S.; Hariri, R.; Kouhsoltani, M.; Shokri, J.; Javadzadeh, Y.; Hamishehkar, H. Enhanced Stability and Dermal Delivery of Hydroquinone Using Solid Lipid Nanoparticles. Colloids Surf. B Biointerfaces 2015, 136, 1004–1010. [Google Scholar] [CrossRef]
  120. Al-Amin, M.; Cao, J.; Naeem, M.; Banna, H.; Kim, M.-S.; Jung, Y.; Chung, H.Y.; Moon, H.R.; Yoo, J.-W. Increased Therapeutic Efficacy of a Newly Synthesized Tyrosinase Inhibitor by Solid Lipid Nanoparticles in the Topical Treatment of Hyperpigmentation. Drug Des. Dev. Ther. 2016, 10, 3947. [Google Scholar] [CrossRef] [Green Version]
  121. Shrotriya, S.; Ranpise, N.; Satpute, P.; Vidhate, B. Skin Targeting of Curcumin Solid Lipid Nanoparticles-Engrossed Topical Gel for the Treatment of Pigmentation and Irritant Contact Dermatitis. Artif. Cells Nanomed. Biotechnol. 2018, 46, 1471–1482. [Google Scholar] [CrossRef] [Green Version]
  122. Ayuningtyas, I.N.; Mun’im, A.; Sutriyo, S. The Study of Safety and Skin Whitening Efficacy of Melinjo (Gnetum Gnemon L.) Seed Extract-Loaded Lipid Particle Gel. Pharmacogn. Res. 2018, 10, 432–436. [Google Scholar]
  123. Kumar, A.; Rao, R. Enhancing Efficacy and Safety of Azelaic Acid via Encapsulation in Cyclodextrin Nanosponges: Development, Characterization and Evaluation. Polym. Bull. 2021, 78, 5275–5302. [Google Scholar] [CrossRef]
  124. ElHoffy, N.; Elezaby, R.; Nasr, M.; Osama, A.; Elkheshen, S. Optimization of the Colloidal Properties of Chitosan Nanoparticles Encapsulating Alpha-Arbutin. Arch. Pharm. Sci. Ain Shams Univ. 2022, 6, 17–28. [Google Scholar]
  125. Hatem, S.; Elkheshen, S.A.; Kamel, A.O.; Nasr, M.; Moftah, N.H.; Ragai, M.H.; Elezaby, R.S.; El Hoffy, N.M. Functionalized Chitosan Nanoparticles for Cutaneous Delivery of a Skin Whitening Agent: An Approach to Clinically Augment the Therapeutic Efficacy for Melasma Treatment. Drug Deliv. 2022, 29, 1212–1231. [Google Scholar] [CrossRef] [PubMed]
  126. Li, J.; Duan, N.; Song, S.; Nie, D.; Yu, M.; Wang, J.; Xi, Z.; Li, J.; Sheng, Y.; Xu, C. Transfersomes Improved Delivery of Ascorbic Palmitate into the Viable Epidermis for Enhanced Treatment of Melasma. Int. J. Pharm. 2021, 608, 121059. [Google Scholar] [CrossRef]
  127. Radmard, A.; Saeedi, M.; Morteza-Semnani, K.; Hashemi, S.M.H.; Nokhodchi, A. An Eco-Friendly and Green Formulation in Lipid Nanotechnology for Delivery of a Hydrophilic Agent to the Skin in the Treatment and Management of Hyperpigmentation Complaints: Arbutin Niosome (Arbusome). Colloids Surf. B Biointerfaces 2021, 201, 111616. [Google Scholar] [CrossRef]
  128. Fachinetti, N.; Rigon, R.B.; Eloy, J.O.; Sato, M.R.; Dos Santos, K.C.; Chorilli, M. Comparative Study of Glyceryl Behenate or Polyoxyethylene 40 Stearate-Based Lipid Carriers for Trans-Resveratrol Delivery: Development, Characterization and Evaluation of the in Vitro Tyrosinase Inhibition. AAPS PharmSciTech 2018, 19, 1401–1409. [Google Scholar] [CrossRef]
  129. Wu, P.-S.; Lin, C.-H.; Kuo, Y.-C.; Lin, C.-C. Formulation and Characterization of Hydroquinone Nanostructured Lipid Carriers by Homogenization Emulsification Method. J. Nanomater. 2017, 2017, 3282693. [Google Scholar] [CrossRef] [Green Version]
  130. Tofani, R.P.; Sumirtapura, Y.C.; Darijanto, S.T. Formulation, Characterisation, and in Vitro Skin Diffusion of Nanostructured Lipid Carriers for Deoxyarbutin Compared to a Nanoemulsion and Conventional Cream. Sci. Pharm. 2016, 84, 634–645. [Google Scholar] [CrossRef] [Green Version]
  131. Kim, B.-S.; Na, Y.-G.; Choi, J.-H.; Kim, I.; Lee, E.; Kim, S.-Y.; Lee, J.-Y.; Cho, C.-W. The Improvement of Skin Whitening of Phenylethyl Resorcinol by Nanostructured Lipid Carriers. Nanomaterials 2017, 7, 241. [Google Scholar] [CrossRef]
  132. Aliasgharlou, L.; Ghanbarzadeh, S.; Azimi, H.; Zarrintan, M.H.; Hamishehkar, H. Nanostructured Lipid Carrier for Topical Application of N-Acetyl Glucosamine. Adv. Pharm. Bull. 2016, 6, 581. [Google Scholar] [CrossRef] [Green Version]
  133. Parveen, R.; Akhtar, N.; Mahmood, T. Topical Microemulsion Containing Punica Granatum Extract: Its Control over Skin Erythema and Melanin in Healthy Asian Subjects. Adv. Dermatol. Allergol. Dermatol. Alergol. 2014, 31, 351–355. [Google Scholar] [CrossRef] [Green Version]
  134. Pakpayat, N.; Nielloud, F.; Fortuné, R.; Tourne-Peteilh, C.; Villarreal, A.; Grillo, I.; Bataille, B. Formulation of Ascorbic Acid Microemulsions with Alkyl Polyglycosides. Eur. J. Pharm. Biopharm. 2009, 72, 444–452. [Google Scholar] [CrossRef]
  135. Azhar, S.N.A.S.; Ashari, S.E.; Salim, N. Development of a Kojic Monooleate-Enriched Oil-in-Water Nanoemulsion as a Potential Carrier for Hyperpigmentation Treatment. Int. J. Nanomed. 2018, 13, 6465. [Google Scholar] [CrossRef] [Green Version]
  136. Al-Edresi, S.; Baie, S. Formulation and Stability of Whitening VCO-in-Water Nano-Cream. Int. J. Pharm. 2009, 373, 174–178. [Google Scholar] [CrossRef]
Figure 1. Various stages of melanin life cycle (i) melanocyte activation, (ii) melanosome development, (iii) melanin production, (iv) melanin distribution and (v) melanin removal.
Figure 1. Various stages of melanin life cycle (i) melanocyte activation, (ii) melanosome development, (iii) melanin production, (iv) melanin distribution and (v) melanin removal.
Molecules 28 00220 g001
Figure 2. The mechanism of action of anti-hyperpigmentation drugs via topical application.
Figure 2. The mechanism of action of anti-hyperpigmentation drugs via topical application.
Molecules 28 00220 g002
Figure 3. Structural representation of various lipid based nanocarriers.
Figure 3. Structural representation of various lipid based nanocarriers.
Molecules 28 00220 g003
Table 1. Fitzpatrick skin phototype classification system on the basis of skin texture and propensity to tan or burn.
Table 1. Fitzpatrick skin phototype classification system on the basis of skin texture and propensity to tan or burn.
Skin TypeSkin TextureAptitude to Tan
IBlond/red hair, blond/red complexion, blue/green eyesNever tan, always burn
IIBlond skin, blue eyesUsually burn, difficulty in tan
IIIWhite skin with a deeper hueAverage tan, early burn
IVModerate brown skinBurns minimally, tans simply
VSkin colour: dark brownHardly ever burns, tans very easily
VISkin colour: blackAlways tans darkly and never burns
Table 2. The summary of research outcomes of nanocarriers based topical drug delivery explored for the management of melasma and other hyper-pigmentation disorders.
Table 2. The summary of research outcomes of nanocarriers based topical drug delivery explored for the management of melasma and other hyper-pigmentation disorders.
Drug (Technique)ExcipientsOutcome & SignificanceRef.
Solid Lipid Nanoparticles
Kojic acid (high speed homogenisation and ultra-probe sonication method)Cholesterol, Glyceryl monostearate, Tween 20, Span 60Enhanced the cutaneous delivery of Kojic acid with increased concentration and controlled drug release into deeper skin layers[115]
Econazole nitrate (High-shear homogenization method)Precirol ATO 5, Tween 80Increased permeation of drug within 1 h of its application and possessed better penetration of drug into deeper layers of skin after 3 h[116]
Miconazole nitrate (High-pressure homogenization)Compritol 888, Propylene glycol, Tween 80, Glyceryl monostearateImproved skin targeting effect and accumulative absorption of drug in the skin[117]
N-Acetyl-D-Glucosamine (High shear homogenization)Cetyl Palmitate, Phosphatidylcholine, Hydrogenated Castor OilImprovement of skin hydration and elasticity in several skin disorders[118]
Hydroquinone (Hot melt homogenization method)Poloxamer 407, Glycerol PalmitostearateExcellent physicochemical stability and improved drug localisation in the skin[119]
Tyrosinase inhibitor-(Z)-5-(2,4-dihydroxy benzylidene)thiazolidine-2,4-dione (MHY498) (o/w emulsion solvent-evaporation method)Compritol 888 ATO, Phosphatidylcholine, Poloxamer 188MHY-SLNs exhibited prolonged release and increased skin permeation and effectively prevented UVB-induced melanogenesis[120]
Curcumin (Pre-emulsion technique followed by ultrasonic probe sonication method)Precirol ATO5, Tween-80Curcumin-SLN exhibited controlled drug release up to 24 h. It showed potential for skin targeting and has potential in skin depigmentation[121]
Melinjo (Gnetum gnemon L.) seed extract (High-shear homogenization and hot-melted technique)Glyceryl monostearate, Brij CS25Melinjo seed extract produced skin whitening effect without causing irritation [122]
Nanosponges
Azelaic acid (Melt method)β-Cyclodextrin, diphenyl carbonateBeta cyclodextrin nanosponges increased the solubility and depigmenting action of Azelaic acid via antioxidant and antityrosinase effects[123]
Polymeric Nanoparticles
Alpha-arbutin (Ionic gelation method)Chitosan, tripolyphosphate sodium saltLoading of α-arbutin into chitosan produced significant higher entrapment efficiency as compared to α-arbutin loading into tripolyphosphate[124]
Alpha-arbutin (Ionic gelation method)Chitosan, tripolyphosphate sodium salt, hyaluronic acid, collagenAlpha-arbutin loaded chitosan nanoparticles hydrogels revealed better therapeutic effectiveness in melasma as compared to free drug hydrogels and also exhibited improved drug deposition into deep skin layers[125]
Vitamin C (Modified solvent evaporation technique)Ethyl cellulose, Pluronic F127Polymeric nanoparticles showed sustained release behaviour till 8 h and significantly improved the therapeutic response and decreased adverse effects[107]
Glabridin (Pressure homogenization method)Partially myristoylated chitosan pyrrolidone carboxylate (PMCP), Polyquaternium-64, Tween 60, Butylene glycol, Cetyl ethylhexanoate,PMCP was found efficient transdermal drug carrier for enhancing the permeation of Glabridin into epidermis of skin and suppressed the synthesis of melanin in skin[114]
Aspasomes
Mg ascorbyl phosphate (Film hydration method)Lecithin, cholesterolAspasome based cream exhibited enhanced drug permeation and skin retention and showed clinical effectiveness in melasma equivalent to 15% trichloroacetic acid[74]
Transferosomes
Ascorbic palmitate (Thin-film hydration method)Soybean phosphatidylcholine, Sodium deoxycholateThe permeation of ascorbic palmitate from transferosomes based drug delivery was higher which leads to 14.1-fold increase in ascorbic palmitate accumulation in epidermis in comparison to plain drug [126]
Ethosomes
Phenylethyl Resorcinol (Thin-film hydration method)Soybean phosphatidylcholine, CholesterolEthosomes showed increased tyrosinase inhibition activity and also decreased melatonin content as compared to other formulations in B16 melanoma cells[60]
Niosomes
Arbutin (Ultrasonic technique)Cholesterol, Tween 20, Span 20Research study illustrated higher drug deposition in skin layers and revealed no signs of cytotoxicity in in-vitro cytotoxicity test and non-irritancy on Wistar rats [127]
Nanostructured Lipid Carrier
Trans-Resveratrol (High shear homogenization technique)Glyceryl behenate, Poloxamer 407, PEG-40 stearate, Castor oil, Caprylic/capric triglyceridesNLCs developed with PEG-40 stearate leads to 1.31 and 1.83-fold higher tyrosinase inhibition as compared to NLCs prepared with glyceryl behenate and plain trans-resveratrol solution[128]
Hydroquinone (Homogenization emulsification method)Sodium hydrogen sulfite, Bees wax, Caprylic/capric triglyceride, Lecithin, Span 80Hydroquinone loaded in NLC showed enhanced permeability, improved light stability and exhibited higher tyrosinase inhibition rate[129]
Deoxyarbutin (High-shear homogenisation and ultrasonication)Cetyl palmitate, Myristyl myristate, Poloxamer 188, PEG-400, Sodium sulfiteIncreased efficacy of deoxyarbutin to inhibit tyrosinase activity during melanogenesis in skin[130]
Phenylethyl Resorcinol (Hot-melted ultrasonic method)Glyceryl monostearate, Olive oil, Lecithin, Tween 80, Polyvinyl alcoholPhenylethyl Resorcinol loaded NLCs have particle size, polydispersity index, encapsulation efficiency and loading capacity of 57.9 ± 1.3 nm, 0.24 ± 0.01, 93.1 ± 4.2% and 8.5 ± 0.4%, respectively and exhibited sustained release pattern[131]
N-Acetyl Glucosamine (Hot homogenization technique) Miglyol, Precirol, Poloxamer, Tween 80 N-Acetyl Glucosamine loaded NLCs have particle size of 190 nm, loading capacity of 9% and revealed significant decrease in melanin distribution pattern [132]
Liposomes
Niacinamide (High-pressure homogenization method)Phosphatidylcholine, Cholesterol, Ceramide, Dipotassium glycyrrhizateFlexible liposomes synthesized in this research demonstrated higher deformability, safety, skin permeability, and anti-melanogenesis activity in comparison to conventional liposomes [71]
Tranexamic Acid (Fusion method)Soybean phosphatidylcholine, Cholesterol, Propylene glycolImmense reduction in MASI scores was observed in patients treated with 5% liposomal tranexamic acid in comparison with patients treated with 4% hydroquinone cream and no serious adverse effects were observed in patients treated with liposomes[49]
Anthocyanin (Vaporization and dehydration-hydration of organic solution)Lecithin, CholesterolEncapsulation of anthocyanin into liposomes enhanced its stability and reduced melanogenesis by inhibition of tyrosinase and suppression of protein expression of tyrosinase and microphthalmia-associated transcription factor[52]
Asparagus racemosus extracts (Chloroform-film, Reverse-phase evaporation, Polyol dilution, Freeze-drying of monophase solution methods)Lecithin, Phospholipon, Diosgenin, Cholesterol, Propylene glycolLiposomes had particle size in range of 0.26–13.83 μm and zeta potentials of −1.5 to −39.3 mV. The liposomes prepared by polyol dilution containing lecithin had maximum entrapment efficiency and in-vitro tyrosinase inhibitory activity of 69.08% and 25%, respectively[55]
Phenylethyl Resorcinol (Injection method)Soybean lecithin, Tween 80Liposomes had particle size in range of 160∼170 nm, drug loading of 2.45 ± 0.03% and had excellent stability[56]
Arbutin (Film dispersion method)Soybean Phosphatidylcholine, CholesterolThe deposition of arbutin in epidermis/dermis layer of skin from liposome was higher in comparison to plain arbutin [58]
Microemulsion
Punica granatum extract (Spontaneous emulsification technique phase titration method)Tween 80, Propylene Glycol, Palm oilMicroemulsion revealed skin compatibility and exhibited reduction in skin melanin content in healthy male volunteers[133]
Ascorbic acid (Hydrophilic lipophilic deviation concept)Dioctylcyclohexane, Sorbitan monolaurate, Decylglucoside, Mineral oilMicroemulsion showed transcutaneous penetration of ascorbic acid which illustrated ascorbic acid-loaded microemulsion as suitable cosmetic for skin whitening potential[134]
Nanoemulsion
Kojic monooleate (High and low energy emulsification technique)Lemon essential oil, Castor oil, Tween 80, Xanthan gumCytotoxicity assay of nanoemulsion on mouse embryonic fibroblast cell line revealed safety and suitability of formulation in cosmeceutical application[135]
Virgin coconut oil (Condensation method)Squalene oil, Emulium Kappa, Propylene glycolAddition of squalene oil caused reduction in ostwald ripening and increased stability of formulation[136]
SLN: solid lipid nanoparticles; NLC: nanostructured lipid carriers.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Singh, S.; Sharma, N.; Zahoor, I.; Behl, T.; Antil, A.; Gupta, S.; Anwer, M.K.; Mohan, S.; Bungau, S.G. Decrypting the Potential of Nanotechnology-Based Approaches as Cutting-Edge for Management of Hyperpigmentation Disorder. Molecules 2023, 28, 220. https://doi.org/10.3390/molecules28010220

AMA Style

Singh S, Sharma N, Zahoor I, Behl T, Antil A, Gupta S, Anwer MK, Mohan S, Bungau SG. Decrypting the Potential of Nanotechnology-Based Approaches as Cutting-Edge for Management of Hyperpigmentation Disorder. Molecules. 2023; 28(1):220. https://doi.org/10.3390/molecules28010220

Chicago/Turabian Style

Singh, Sukhbir, Neelam Sharma, Ishrat Zahoor, Tapan Behl, Anita Antil, Sumeet Gupta, Md Khalid Anwer, Syam Mohan, and Simona Gabriela Bungau. 2023. "Decrypting the Potential of Nanotechnology-Based Approaches as Cutting-Edge for Management of Hyperpigmentation Disorder" Molecules 28, no. 1: 220. https://doi.org/10.3390/molecules28010220

APA Style

Singh, S., Sharma, N., Zahoor, I., Behl, T., Antil, A., Gupta, S., Anwer, M. K., Mohan, S., & Bungau, S. G. (2023). Decrypting the Potential of Nanotechnology-Based Approaches as Cutting-Edge for Management of Hyperpigmentation Disorder. Molecules, 28(1), 220. https://doi.org/10.3390/molecules28010220

Article Metrics

Back to TopTop